What is Halozyme?
Halozyme is a premier biotechnology enterprise dedicated to the advancement of drug delivery technologies. The company is best known for its proprietary platform that facilitates the subcutaneous administration of biologic medicines, effectively transforming therapies that traditionally necessitate intravenous infusion. This innovation not only enhances patient convenience but also optimizes the commercial viability of complex biologic drugs. By operating a dual-revenue model that combines internal therapeutic development with strategic licensing arrangements, Halozyme has established a resilient business structure. The firm's ability to integrate its technology into the pipelines of global pharmaceutical leaders has cemented its role as an essential partner in the modern biopharmaceutical ecosystem, bridging the gap between scientific discovery and patient-centric delivery.
How much funding has Halozyme raised?
Halozyme has raised a total of $1.1B across 10 funding rounds:
Corporate Investment
$5.5M
Stock Offering
$38.2M
Stock Offering
$60M
Stock Offering
$81.8M
Debt
$50M
Stock Offering
$107.8M
Debt
$150M
Stock Offering
$135M
Debt
$400M
Corporate Investment (2009): $5.5M led by Baxter Healthcare Corporation
Stock Issuance/Offering (2009): $38.2M supported by Undisclosed
Stock Issuance/Offering (2010): $60M featuring Undisclosed
Stock Issuance/Offering (2012): $81.8M backed by Undisclosed
Debt (2014): $50M with participation from Silicon Valley Bank and Oxford Finance
Stock Issuance/Offering (2014): $107.8M led by Undisclosed
Debt (2016): $150M supported by Athyrium Capital Management and Pharmakon Advisors
Stock Issuance/Offering (2017): $135M featuring Undisclosed
Debt (2019): $400M backed by Undisclosed
Key Investors in Halozyme
Athyrium Capital Management
Athyrium Capital Management is a leading investment management platform focused on structured investments in the global healthcare sector, providing financing solutions that support growth objectives.
Silicon Valley Bank
SVB Financial Group offers commercial and private banking, asset management, and specialized investment services tailored to the needs of the innovation economy.
Oxford Finance
Oxford Finance is a specialty finance firm that offers flexible financial solutions and debt capital to healthcare and life sciences companies worldwide.
What's next for Halozyme?
Looking ahead, Halozyme is poised to capitalize on its established technological infrastructure to drive further growth in the biopharmaceutical market. The recent strategic investment provides the necessary liquidity to deepen its research pipeline and broaden the application of its subcutaneous delivery systems. As the industry shifts toward more patient-friendly administration methods, Halozyme's focus on scaling its licensing arrangements and expanding its collaborative network will be critical. The company is expected to prioritize the commercialization of its existing partnerships while exploring new therapeutic areas where its enzyme-based solutions can provide a competitive advantage. By maintaining a disciplined approach to capital allocation and strategic expansion, Halozyme remains a key player in the evolution of global healthcare delivery.
See full Halozyme company page
